248 related articles for article (PubMed ID: 8680901)
1. Interleukin-1 receptor antagonist in differential diagnosis of inflammatory bowel diseases.
Propst A; Propst T; Herold M; Vogel W; Judmaier G
Eur J Gastroenterol Hepatol; 1995 Nov; 7(11):1031-6. PubMed ID: 8680901
[TBL] [Abstract][Full Text] [Related]
2. Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease.
Hyams JS; Fitzgerald JE; Wyzga N; Treem WR; Justinich CJ; Kreutzer DL
Dig Dis Sci; 1994 Sep; 39(9):1893-9. PubMed ID: 8082495
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
Niederau C; Backmerhoff F; Schumacher B; Niederau C
Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
[TBL] [Abstract][Full Text] [Related]
4. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease.
Mazlam MZ; Hodgson HJ
Gut; 1992 Jun; 33(6):773-8. PubMed ID: 1624158
[TBL] [Abstract][Full Text] [Related]
6. Colonic mucosal interleukin 1 receptor antagonist in inflammatory bowel disease.
Nishiyama T; Mitsuyama K; Toyonaga A; Sasaki E; Tanikawa K
Digestion; 1994; 55(6):368-73. PubMed ID: 7705549
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity.
Oikonomou KA; Kapsoritakis AN; Theodoridou C; Karangelis D; Germenis A; Stefanidis I; Potamianos SP
J Gastroenterol; 2012 May; 47(5):519-30. PubMed ID: 22200942
[TBL] [Abstract][Full Text] [Related]
8. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification.
Isaacs KL; Sartor RB; Haskill S
Gastroenterology; 1992 Nov; 103(5):1587-95. PubMed ID: 1426879
[TBL] [Abstract][Full Text] [Related]
9. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease.
Ludwiczek O; Vannier E; Borggraefe I; Kaser A; Siegmund B; Dinarello CA; Tilg H
Clin Exp Immunol; 2004 Nov; 138(2):323-9. PubMed ID: 15498044
[TBL] [Abstract][Full Text] [Related]
10. Imbalance of the interleukin 1 system in colonic mucosa--association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2.
Andus T; Daig R; Vogl D; Aschenbrenner E; Lock G; Hollerbach S; Köllinger M; Schölmerich J; Gross V
Gut; 1997 Nov; 41(5):651-7. PubMed ID: 9414973
[TBL] [Abstract][Full Text] [Related]
11. Increased circulating levels of interleukin-1 receptor antagonist in patients with inflammatory bowel disease.
Kuboyama S
Kurume Med J; 1998; 45(1):33-7. PubMed ID: 9658748
[TBL] [Abstract][Full Text] [Related]
12. Relationship of interleukin-1 receptor antagonist to mucosal inflammation in inflammatory bowel disease.
Hyams JS; Fitzgerald JE; Wyzga N; Muller R; Treem WR; Justinich CJ; Kreutzer DL
J Pediatr Gastroenterol Nutr; 1995 Nov; 21(4):419-25. PubMed ID: 8583293
[TBL] [Abstract][Full Text] [Related]
13. INTERACTIONS AMONG INTERLEUKIN-6, C-REACTIVE PROTEIN AND INTERLEUKIN-6 (-174) G/C POLYMORPHISM IN THE PATHOGENESIS OF CROHN'S DISEASE AND ULCERATIVE COLITIS.
Takač B; Mihaljević S; Glavaš-Obrovac L; Kibel A; Suver-Stević M; Canecki-Varžić S; Samardžija M; Rajkovac I; Kovač D; Štefanić M
Acta Clin Croat; 2020 Mar; 59(1):67-80. PubMed ID: 32724277
[TBL] [Abstract][Full Text] [Related]
14. Human alpha defensin 5 is a candidate biomarker to delineate inflammatory bowel disease.
Williams AD; Korolkova OY; Sakwe AM; Geiger TM; James SD; Muldoon RL; Herline AJ; Goodwin JS; Izban MG; Washington MK; Smoot DT; Ballard BR; Gazouli M; M'Koma AE
PLoS One; 2017; 12(8):e0179710. PubMed ID: 28817680
[TBL] [Abstract][Full Text] [Related]
15. Activation of NLRP3 Inflammasome in Inflammatory Bowel Disease: Differences Between Crohn's Disease and Ulcerative Colitis.
Lazaridis LD; Pistiki A; Giamarellos-Bourboulis EJ; Georgitsi M; Damoraki G; Polymeros D; Dimitriadis GD; Triantafyllou K
Dig Dis Sci; 2017 Sep; 62(9):2348-2356. PubMed ID: 28523573
[TBL] [Abstract][Full Text] [Related]
16. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
Ciećko-Michalska I; Fedak D; Mach T
Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
[TBL] [Abstract][Full Text] [Related]
17. Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD).
Dionne S; D'Agata ID; Hiscott J; Vanounou T; Seidman EG
Clin Exp Immunol; 1998 Jun; 112(3):435-42. PubMed ID: 9649212
[TBL] [Abstract][Full Text] [Related]
18. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.
Reinecker HC; Steffen M; Witthoeft T; Pflueger I; Schreiber S; MacDermott RP; Raedler A
Clin Exp Immunol; 1993 Oct; 94(1):174-81. PubMed ID: 8403503
[TBL] [Abstract][Full Text] [Related]
19. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease.
Bross DA; Leichtner AM; Zurakowski D; Law T; Bousvaros A
J Pediatr Gastroenterol Nutr; 1996 Aug; 23(2):164-71. PubMed ID: 8856584
[TBL] [Abstract][Full Text] [Related]
20. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation.
Casini-Raggi V; Kam L; Chong YJ; Fiocchi C; Pizarro TT; Cominelli F
J Immunol; 1995 Mar; 154(5):2434-40. PubMed ID: 7868909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
